The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Fri., Sep. 30, 4:20 PM

Slide #8. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) 1 for 30 Reverse Split

Announced: 9/12/2022
Stock Split: 1 for 30
Record Date: 9/12/2022
Pay Date: 9/13/2022
NRBO Optionable?: Yes

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. ANA001, Co.'s drug candidate, is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease (patients not requiring ventilators). Co.'s NB-01 addresses various mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. Co.'s NB-02 is in development for the symptomatic and disease modifying treatment of neurodegenerative diseases, including Alzheimer's disease and tauopathies. Co.'s Gemcabene is an oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides.
NRBO Detailed Information Page & Split History »

Company Name: 
NeuroBo Pharmaceuticals Inc
Website: 
www.neurobopharma.com
Sector: 
Biotechnology
Number of ETFs Holding NRBO: 
1
Total Market Value Held by ETFs: 
$4.02M
Total Market Capitalization: 
$12.00M
% of Market Cap. Held by ETFs: 
33.49%

Open the NRBO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree NRBO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
80th percentile
(ranked higher than approx. 80% of all stocks covered)

Analysts' Target Price:
NRBO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Stock Splits Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.